Vasodilator-stimulated phosphoprotein phosphorylation analysis prior to percutaneous coronary intervention for exclusion of postprocedural major adverse cardiovascular events - PubMed (original) (raw)
Vasodilator-stimulated phosphoprotein phosphorylation analysis prior to percutaneous coronary intervention for exclusion of postprocedural major adverse cardiovascular events
L Bonello et al. J Thromb Haemost. 2007 Aug.
Free article
Abstract
Background: Despite dual antiplatelet therapy, the rate of major adverse cardiovascular events (MACE) after percutaneous coronary angioplasty remains high. Studies have shown interindividual variations in response to clopidogrel. Furthermore, there is an apparent link between clinical outcomes and clopidogrel resistance.
Objectives: To investigate the value of platelet reactivity index (PRI), assessed by vasodilator-stimulated phosphoprotein (VASP) phosphorylation analysis, for predicting MACE after percutaneous coronary intervention (PCI) with stent implantation.
Methods: A prospective monocentric study was performed on 144 patients undergoing PCI. PR was evaluated by VASP phosphorylation analysis 24 h after they received a 300-mg loading dose of clopidogrel. MACE were recorded during a 6-month follow-up. Patients were divided into quintiles according to PRI, as assessed by VASP analysis. The receiver operating characteristic (ROC) curve served to determine the optimal cut-off value of VASP analysis to detect MACE.
Results: Of the 144 patients, 34% had stable angina pectoris, 40% silent ischemia, and 26% low-risk non-ST-segment elevation acute coronary syndrome. During the follow-up, 21 MACE were observed. Patients in quintile 1 of VASP analysis had a significantly lower risk of MACE as compared with those among the four higher quintiles (0 vs. 21, P < 0.01). ROC curve analysis of VASP showed an optimal cut-off value of 50% PR to exclude MACE. The negative predictive value of the test was 100%.
Conclusions: VASP phosphorylation analysis can evaluate the individual response to clopidogrel loading dose prior to PCI and predict postprocedural MACE.
Similar articles
- Modifying clopidogrel maintenance doses according to vasodilator-stimulated phosphoprotein phosphorylation index improves clinical outcome in patients with clopidogrel resistance.
Wang XD, Zhang DF, Zhuang SW, Lai Y. Wang XD, et al. Clin Cardiol. 2011 May;34(5):332-8. doi: 10.1002/clc.20884. Epub 2011 Apr 27. Clin Cardiol. 2011. PMID: 21538380 Free PMC article. Clinical Trial. - Multiple electrode aggregometry and vasodilator stimulated phosphoprotein-phosphorylation assay in clinical routine for prediction of postprocedural major adverse cardiovascular events.
Freynhofer MK, Brozovic I, Bruno V, Farhan S, Vogel B, Jakl G, Willheim M, Hübl W, Wojta J, Huber K. Freynhofer MK, et al. Thromb Haemost. 2011 Aug;106(2):230-9. doi: 10.1160/TH11-02-0077. Epub 2011 May 26. Thromb Haemost. 2011. PMID: 21614416 - Impact of P2Y12 inhibition by clopidogrel on cardiovascular mortality in unselected patients treated by percutaneous coronary angioplasty: a prospective registry.
El Ghannudi S, Ohlmann P, Meyer N, Wiesel ML, Radulescu B, Chauvin M, Bareiss P, Gachet C, Morel O. El Ghannudi S, et al. JACC Cardiovasc Interv. 2010 Jun;3(6):648-56. doi: 10.1016/j.jcin.2010.03.003. JACC Cardiovasc Interv. 2010. PMID: 20630458 - Relationship between pharmacokinetics and pharmacodynamics of clopidogrel in patients undergoing percutaneous coronary intervention: comparison between vasodilator-stimulated phosphoprotein phosphorylation assay and multiple electrode aggregometry.
Danese E, Fava C, Beltrame F, Tavella D, Calabria S, Benati M, Gelati M, Gottardo R, Tagliaro F, Guidi GC, Cattaneo M, Minuz P. Danese E, et al. J Thromb Haemost. 2016 Feb;14(2):282-93. doi: 10.1111/jth.13197. Epub 2016 Jan 29. J Thromb Haemost. 2016. PMID: 26576037 - Effect of high-dose clopidogrel according to CYP2C19*2 genotype in patients undergoing percutaneous coronary intervention- a systematic review and meta-analysis.
Zhang L, Yang J, Zhu X, Wang X, Peng L, Li X, Cheng P, Yin T. Zhang L, et al. Thromb Res. 2015 Mar;135(3):449-58. doi: 10.1016/j.thromres.2014.12.007. Epub 2014 Dec 9. Thromb Res. 2015. PMID: 25511576 Review.
Cited by
- Platelet function testing in patients with acute coronary syndrome.
Orban M, Sibbing D. Orban M, et al. J Cardiovasc Transl Res. 2013 Jun;6(3):371-7. doi: 10.1007/s12265-013-9450-7. Epub 2013 Feb 9. J Cardiovasc Transl Res. 2013. PMID: 23397280 Review. - Towards personalized medicine based on platelet function testing for stent thrombosis patients.
Godschalk TC, Hackeng CM, Ten Berg JM. Godschalk TC, et al. Thrombosis. 2012;2012:617098. doi: 10.1155/2012/617098. Epub 2012 Dec 25. Thrombosis. 2012. PMID: 23320159 Free PMC article. - Platelet function testing to predict hyporesponsiveness to clopidogrel in patients with chest pain seen in the emergency department.
Sharma RK, Erickson SW, Sharma R, Voelker DJ, Reddy HK, Dod H, Marsh JD. Sharma RK, et al. Vasc Health Risk Manag. 2013;9:187-93. doi: 10.2147/VHRM.S43909. Epub 2013 May 1. Vasc Health Risk Manag. 2013. PMID: 23662064 Free PMC article. - Monitoring aspirin and clopidogrel response: testing controversies and recommendations.
Karathanos A, Geisler T. Karathanos A, et al. Mol Diagn Ther. 2013 Jun;17(3):123-37. doi: 10.1007/s40291-013-0022-y. Mol Diagn Ther. 2013. PMID: 23588781 Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous